NeurAxis to Showcase Neuromodulation Advances
NeurAxis, Inc. (NYSE American: NRXS), a leader in medical technology focused on innovative neuromodulation therapies, has announced its participation in an important event: the Planet MicroCap Showcase: VEGAS 2025 in partnership with MicroCapClub. This showcase will be held on an exciting day aimed at promoting cutting-edge health technologies.
Details of the Presentation
The presentation is scheduled for Wednesday, April 23, 2025, and NeurAxis's CEO, Brian Carico, will take the stage to share the company’s latest breakthroughs. His insights will illuminate how NeurAxis is addressing chronic and debilitating conditions affecting both children and adults through advanced medical solutions.
Engagement with Investors
In addition to the presentation, NeurAxis will be participating in 1x1 investor meetings on Thursday, April 24, 2025. These personalized meetings provide investors the opportunity to engage directly with the company's leadership and gain deeper insights into NeurAxis’s strategic direction. These meetings will be held in person at the Paris Hotel & Casino in Las Vegas, NV.
Accessing the Presentation
If you're interested in watching the presentation live, it will start at 11:00 AM EST. Attendees can access the presentation through a webcast link provided by the conference organizers. This link is designed to make it easy for participants to engage from anywhere.
Registration Information
For those looking to attend the 1x1 meetings, it’s crucial to ensure you are registered for the event. Registration details can be found on the MicroCap Showcase’s official site. Booking these meetings is an excellent way to gain firsthand knowledge about NeurAxis’s trajectory and the innovative therapies they are developing.
About NeurAxis, Inc.
NeurAxis, Inc. is dedicated to revolutionizing neuromodulation therapies to treat chronic conditions. Their flagship product, IB-Stim™, is an FDA-cleared device that utilizes Percutaneous Electrical Nerve Field Stimulation (PENFS) technology. It specifically addresses functional abdominal pain associated with irritable bowel syndrome (IBS) in adolescents aged 8 to 21.
Commitment to Research
The company is actively engaged in clinical trials that explore the efficacy of its PENFS technology in various conditions that presently lack effective treatment options. This research is part of their ongoing commitment to enhance health outcomes for patients across different demographics.
Future Prospects for NeurAxis
As NeurAxis continues to expand its research and development capabilities, they are optimistic about the future. The company is committed to fostering innovation in the medical technology sector, with a focus on addressing unmet healthcare needs. Their ongoing efforts seek to turn innovative ideas into actionable solutions for patient care.
Frequently Asked Questions
What is the Planet MicroCap Showcase?
The Planet MicroCap Showcase is an event designed for microcap and emerging growth companies to present their innovations to investors and industry experts.
When will NeurAxis present at the event?
NeurAxis will present on Wednesday, April 23, 2025, at 11:00 AM EST.
What is IB-Stim™ therapy?
IB-Stim™ is a neuromodulation therapy developed by NeurAxis, using PENFS technology to treat functional abdominal pain associated with IBS in adolescents.
How can I watch the live presentation?
The live presentation can be accessed through a webcast link available on the Planet MicroCap Showcase website.
Who can attend the 1x1 meetings?
Investors registered for the Planet MicroCap Showcase will have the opportunity to attend 1x1 meetings with NeurAxis’s management team.